Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

I agree that the NHS do not want to process more patients, and that is how I looked at the situation, but they have to show they are treating patients efficiently, ie cost effective. The problem is the more incompetent the management show they are, they employ even more managers to sort the mess out. But with many operations now being farmed out to private hospitals, keeping the cost down in these units is important as they are vying for each patient. Competition will win the day.

Greekman - You are correct competition will win the day. However I don't recall the private sector such as Bupa ever placing an order with Deltex. Now surely you'd expect adoption in the private sector before in the public!!

I agree. I have been unable to find any Private British hospital with the cardioQ. Plenty around the world though. Hopefully as more patients are farmed out ( I personally thing the NHS in it's present form has had its day ) to the private sector things will improve for Deltex. But as you say you would expect the private sector to get on board first.

If you also add to this the extreamily slow takeup in the states and within Europe it makes me wonder how long deltex can hold on.... I figure another share placing to raise funds and further dilute shareholder value will come before any such orderbook. I do agree the technology is amazing and results speak for itself making deltexs potential massive. End of the day though sales are needed if this business will suceed and for the past 3 years we've been awaiting a sniff of them.

The "Big Hope" came on 28th July 2004 when Former Chief Executive of UK NHS joined Deltex Medicals Board. Sir Duncan worked for the NHS for 30 years and was Chief Executive from 1989 to 1994, and executive director of Synergy Healthcare PLC and from 1994-2002 was a non-executive director of BUPA.

I for one expected to see Sir Duncan bring home the sales. Nearly 2 years later I have sold Deltex but have kept them on my watchlist awaiting the golden RNS stating contracts signed for "real" signifficant probe and CardioQ sales. Finally CardioQs patient, how long left to get sales and exploit the market before the technology is copied?

THE COUNT--->EXPLOSIVE

For someone who has absolutely no idea, you really do try to come across with a great deal of authority don't you?

The arguments are not quite as simple as you would try to portray.

THE COUNT!

The Count - Please do not even try and go there, lets hear your arguements and what ever kind of spin you'd like to put on this?

As for authority I have none, its a free world mate and a free BB for anyone wanting to post a view, ramper or deramper. All I've done is state the facts, happy to ammend my posts if you can prove me wrong!!

explosive,

Your post 209 hits the nail on the head. As you say take up is slow, although the cardioQ is being used ( albe'it in small quantities ) in quite a few countries.
I think the next 12 months or so will be make or break.

THE COUNT--->EXPLOSIVE

I'll make my further arguments when I am good and ready. I've argued with hundreds of idiots and know alls in the past so I'll pick and choose when, if you don't mind. I am not categorising you in that subset by the way, but many of your arguments are far too simplistic. Just because take up hasn't been immediate and to your shorter timeframes, it is still light years away from meaning that this business model is dead.

They are not as strapped for cash as you would imply, and the cash burn is improving all the time. Read the report in detail before you come out with simple assumptions off the top of your head.

I am preparing a detailed report covering most aspects of the company which I hope to post up hopefully in the next month or so. Hopefully, it might just answer a few of your concerns although it would seem you are not a shareholder so I wonder if you are basing your arguments oin the news at the time when you did hold.

Things move on. This is not static. We all have to be able to take news as it happens and act accordingly, I'm sure you'll agree. And your talk of extremely slow takeup both in the USA and in Europe further shows that you really only have a token understanding of what is at play here.

This is being taken up in the home country of haemodynamic optimisation, and the numbers of both supportive clinical trials and supportive clinicians are growing all the time, albeit slower than people expected a couple of years ago. But they are still growing.

I won't say more now as I would rather answer most concerns in the body of a larger report.

I don't spin. Looking back for a start, my arguments in my single post are not even remotely as simplistic and full of generalisations as yours. We can all sound knowledgable when we are the biggest fish in a little pond, but let's see how things go once a bigger fish or two enters the fray.

You are absolutely right. It is a free world and we all have opinions...but the real crux of the matter boils down to how informed our opinions are and how we draw reasoned analysis from that. You already betray your stance even before any reasoned argument is put your way by talking of the 'spin' I wil put on this. I am usually careful about what I say, and if I don't know enough about a subject, or very little, I tend to shut up rather than show myself up.

Have a good weekend.

THE COUNT!

Thanks Greekman, I agree the next 12 months will be make or break for this company. Will be interesting also to see if another fund raising placement occurs. Anyway good luck to all those holding, you never know I could be back in myself.

T

Greekman - Here here!!

The Count - Look forward to reading your in depth post. You called mine simplistic, generalised and a token understanding but didn't in anyway elaberate. I hope your report contains more useful information than your post 213 which contained none.

With the present climate of Director selling at 3 to 1 of Director buying, it's nice to see this confident announcement.

Ewan Phillips, Finance Director, has notified the
Company that he has today purchased 22,500 ordinary shares at a price of 20.00
pence per share.

Yeh.. good stuff ! let's hope we start to see some good product sales and results !

On todays news they highlighted how the number of NHS beds has been reduced over the last 10 years due to new methods, innovations etc. OK this may be ( and probably is ) yet another political stunt to make out all the ward closures are in order. It did show that the big push to reduce costs was to aim at patients spending less time in hospital. I think we could all give the NHS managers a push ( or should that be a kick ) in the right direction. I wonder if frustration is treated on the NHS.

The FD has bought 4.5K worth of shares, big deal. John Christou bought 1/2million and we have no idea who he is yet, he isn't on the B of D. Skyhigh is right, we need sales of the Cardio Q for the sp to rise, it's no good having a terrific product unless there are buyers for it.
2517

THE COUNT--->2517GEORGE

Why should anyone going over 3% have to be on the board of directors necessarily? Anybody can buy stock in the company.

You will find that all the directors also bought quite heavily shortly after the small funding round around last September.

They do have a terrific product, but the health services of most, if not all countries are notoriously conservative and it can take many years for a technology to be widely adopted as a standard of care. But our SP reflects that...if this was a standard of care in the UK alone, it would mean probe sales of 1m units per year...that could equate quite reasonably to an SP in the region of 10.

So we really do need to get a grip on the actual context here. The key part towards getting very large sales, is to first win over the clinical market and then they will put pressure on those pen pushers that control the purse strings and slowly, slowly, sales will grow.

After a raft of positive trials that do not really leave any doubts as to the effectiveness of the technology both in cost savings to the NHS and in reduction of complications to the patient (and now, one trial could also show that this also saves lives although results of this will not be out for 2 - 3 years yet), the present clinical demand is running at about 10 times actual usage.

And overseas, countries are all very far behind the growth curve that has been illustrated here in the UK. There is a lot and the pressure on the dam is getting greater every day...it could break at any time.

The stock is not overvalued by any meaningful measure, it has awesome medium to long term growth prospects, and although money is tight, they are certainly not in any danger of going bust.

THE COUNT!

This is hilarious.

greekman - 19 May 2006 13:18 - 201 of 221
Mr John Christou recently purchased 500,000 shares. It appears someone has faith. Anyone know who he is.

2517GEORGE - 19 May 2006 13:24 - 202 of 222
No idea, doesn't appear to be on the board of directors @ DEMG.
2517


--snip--


2517GEORGE - 22 May 2006 15:29 - 220 of 222
The FD has bought 4.5K worth of shares, big deal. John Christou bought 1/2million and we have no idea who he is yet, he isn't on the B of D. Skyhigh is right, we need sales of the Cardio Q for the sp to rise, it's no good having a terrific product unless there are buyers for it.
2517


Who is that masked man?

Bet he posts on here.

Yours

John Christou's better looking mate.

2517---> The Count

It's more common that a holder of 3.01% of a co would be either a director or an institution, re the directors buying, yes the FD has 767,156 shares (1%) so I did him a disservice. John Christou is a long term investor and has built up his holding in DEMG over a period of time along with other medical co's, including others which have DEMG's chairman's involvement.

In the USA the co is in discussion with providers and payers in the private sector with a veiw to establish their technology as a standard of care in major surgery, so there is every prospect that good sales figures will result there

Count, I agree the stock is not overvalued. and the outlook is excellent. I had a reponse to an e-mail in 20mins, management appear shareholder friendly, welcoming shareholders to their factory in Chichester.
2517

You tell him George!

Count - dont post about things you don't understand. Do some bloody research!

G

THE COUNT--->GAUSIE

Do you kow the guy? He must be a bit of a crazy....must have more money than sense, eh? :-)

As always, dealing with the NHS is almost bloody impossibel, but they are now making progress and the beauty of the business model is that each monitor sold will generate far more in ongoing consummables for many years to come. The probes cost around 60 a time and it is one per patient so there is plenty of upside once they can get the lumbering juggerbnaut that is the health service to accelerate the take up.

I don't think there is any real doubt of the advantages of haemodynamic optimisation...more and more clinicians are now sold on the idea and just as importantly, NICE have commented that they see this as an acceptable standard of care rather than placing the technology under their remit as they do with most new technologies. This should substantially aid the marketing effort to the dildos that control the NHS purse strings.

Nice of you to look in on this thread.

Regards,

THE COUNT!